CMS Belgium, together with Harvest Law, assisted Celyad Oncology on the deal.
Celyad Oncology, a Belgian biotech company listed on Euronext Brussels/Paris and on the Nasdaq Global Market, structured and implemented of its $25 million At The Market offering (ATM).
Such an ATM transaction is highly innovative for an European issuer and it will allow Celyad to sell shares from time to time on the Nasdaq market for a period of up to 36 months.
The CMS team was led by Vincent Dirckx (Picture) in this operation.
Involved fees earner: Vincent Dirckx – CMS DeBacker;
Law Firms: CMS DeBacker;
Clients: Celyad SA;